Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

The use of an aryl boronic acid carbonyl warhead to target a noncatalytic lysine side chain enables the development of covalent inhibitors against the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1).